ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

NNNN vs ACHV // EV/EBITDA & P/E VALUATION

Anbio Biotechnology (Class A) (NASDAQ) VS. Achieve Life Sciences Inc. (NASDAQ) • 15-METRIC TALLY: NNNN 3 — ACHV 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NNNN VS. ACHV) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC NNNN ACHV SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 87.20% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 17.00% -35.00% +52.00 NNNN /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 91.5x — — TIE /valuation <GO>
Free Cash Flow Yield -1.26% -6.69% +5.43 NNNN /fcf-yield <GO>
Operating Margin 66.70% — — TIE /operating-margins <GO>
Net Profit Margin 68.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 5.60% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 2/9 +3.00 NNNN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 29.4 46.4 -16.98 ACHV /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 77.7x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $535.3M $739.9M -$204.6M ACHV /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR NNNN REV ACHV REV NNNN GROSS % ACHV GROSS % NNNN FCF ACHV FCF
FY 2025 $8.6M $0 87.2% — -$6.7M -$49.5M
FY 2024 $8.2M $0 71.9% — $2.1M -$29.8M
FY 2023 $6.7M $0 — — $898.4K -$24.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NNNN // BETA —
ACHV // BETA —